Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Yemen’s Aden airport shut by STC-backed transport minister, Saudi source says - 2In blow to Lula, Brazil Congress revives controversial environmental bill
- 3Obamacare enrollment declines as US subsidies expire
- 4'Supergirl' drops 1st teaser trailer: Watch Milly Alcock as Kara Zor-El and the return of Krypto the Superdog
- 5Figure out How to Plan for Your Web-based Degree monetarily
- The 15 Most Powerful Forerunners in Business
- 6 Natural products High In Vitamins,Which One Do You Like to Eat
- Most loved Well known Accessory Styles For 2024
- Help Your Business with Master Web based Promoting Arrangements
- Don’t let food poisoning crash your Thanksgiving dinner
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- Getting Your Youngsters' Future: Grasping Legacy Regulations
